Results of EGFR alteration in baseline tumor tissues using Amoy LC10 NGS assay by the central laboratory will be used for publication at the 2024 World Conference on Lung Cancers.
| Title | Results of EGFR alteration in baseline tumor tissues using Amoy LC10 NGS assay by the central laboratory will be used for publication at the 2024 World Conference on Lung Cancers. |
|---|---|
| Description | Amivantamab (Ami) is an EFGR-MET bispecific antibody with immune cell-directing activity. In the PAPILLON (NSC3001) study, ami plus carboplatin-pemetrexed (ami-chemo) demonstrated significantly longer progression-free survival (PFS) vs chemo in patients (pts) with treatment-naive EGFR Exon20 insertion (Ex20ins)-mutated advanced NSCLC (HR,0.40[95% CI,0.30-0.53];P<0.001).To explore whether different Ex20ins sites correlate with PALILLON treatment outcomes, we collected baseline tumor tissues and evaluated the EGFR Ex20ins sites using Amoy LC10 NGS assay. We obserbed consistent benefit favoring ami-chemo across all insertion sites in Exon20, through the correlation analysis between different Ex20ins sites and clinical outcomes. EGFR Ex20ins results will be used for publication at 2024 World Conference on Lung Cancers. |
| Organism | Homo sapiens |
| Data Type | Other Type of Genomic Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA027155 |
| Release Date | 2024-06-19 |
| Submitter | ling zhang (shfkgcp@163.com) |
| Organization | shanghai pulmonary hospital |
| Submission Date | 2024-06-18 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX006700-01 | data backup | 1 | Other Type of Genomic Data | 129.4 KB | xlsx | 0 | Unavailable |